Most people have a type of kidney cancer called clear cell renal cell carcinoma (RCC). A recent study has shown that people with clear cell RCC have a better response to tremelimumab (an anti-CTLA-4 antibody) compared with patients with non-clear cell RCC following a procedure called cryoablation (freezing the tumour using probes through the skin). The results of this pilot study were presented at the 19th Annual Meeting of the International Kidney Cancer Symposium (IKCS 2020).
The researchers suggest this has something to do with the cells (histology) in these kidney cancer tumours, but it is not yet known how anti-CTLA-4 antibodies affect the tumour after cryoablation.
